Catalent

2Q Revenues: $721.4 million (+16%)

2Q Earnings: $45.5 million (-6%)

Comments: Growth in the quarter was primarily driven by the impact of its gene therapy acquisitions, as well as organic growth within the Biologics, Softgel and Oral Technologies, and Clinical Supply Services segments, offset by a decline in the Oral and Specialty Delivery segment. Revenue from the Softgel and Oral Technologies segment was $267.9 million, up 2%. Revenue from the Biologics segment was $225.2 million, an increase of 65% primarily driven by the gene therapy acquisitions, which contributed 56 percentage points to the segment’s revenue growth. Revenue from the Oral and Specialty Delivery segment was $143.2 million, down 7% as a result of decreased volume in the segment’s respiratory and ophthalmic specialty platform due to strong prior-year demand related to an anticipated new product introduction. Revenue from the Clinical Supply Services segment was $87.9 million, an increase of 9% driven by strong demand in the storage and distribution and manufacturing and packaging businesses.